The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs.

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Abstract Text:

Seoung-Ryoung Choi,Prasenjit Mukherjee,Mitchell A Avery,Seoung-Ryoung Choi,Prasenjit Mukherjee,Mitchell A Avery,

Malaria, one of the major reemerging parasitic diseases, is caused by protozoal parasites belonging to the genus plasmodia. Antimalarial drugs have played a mainstream role in controlling the spread of malaria through the treatment of patients infected with the plasmodial parasites and controlling its transmissibility. The current line of therapy against malaria is faced with the hurdles of a low or total lack of efficacy due to the evolution of drug-resistant strains of the malarial parasites. Preventive vaccination against malaria is an ideal solution to this problem but is not expected to arrive for at least a decade. Development of antimalarial drugs involving novel mechanisms of action is therefore of imminent importance. Several novel drug candidates of synthetic and natural products origin as well as their combination therapies are currently being evaluated for their efficacy against the drug-resistant strains of the parasites. Various plasmodial targets/pathways, such as the Purine salvage pathway, Pyrimidine biosynthesis pathway as well as the processes in the apicoplast, have been identified and are being utilized for the discovery and development of novel antimalarial therapies. This review provides an overview of the latest developments in terms of drugs, combination therapies and novel plasmodial targets being carried out to counter the menace of drug-resistant malaria.

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Publishing Authors By Initials

SR Choi,P Mukherjee,MA Avery,SR Choi,P Mukherjee,MA Avery,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current medicinal chemistry

VOLUME: 15

Page Numbers: 161-71

Journal Abbreviation: Curr. Med. Chem.

ISSN: 0929-8673

DAY: 28

MONTH: 01

YEAR: 2008

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9440157

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs.

AFFILIATION: Department of Chemistry, University of Mississippi, University, MS 38677, USA. mavery@olemiss.edu.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Med Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs Related Publications

• A new library of C-16 modified artemisinin analogs and evaluation of their anti-parasitic activities.
• Analysis of CoQ(10) in rat serum by ultra-performance liquid chromatography mass spectrometry after oral administration.
• Behavioural interventions for children and adults with behaviour disorders after TBI: a systematic review of the evidence.
• Cancellation of elective oral and maxillofacial operations.
• Communication gaps and readmissions to hospital for patients aged 75 years and older: observational study.
• Delay in post-op complication diagnosis.
• Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
• Dual roles of autophagy in the survival of Caenorhabditis elegans during starvation.
• Enough blame to go around.
• Faculty Teaching Time: A Comparison of Web-Based and Face-to-Face Graduate Nursing Courses.
• Failure to recognize and treat.
• Failure to respond.
• Fatal surgical error.
• Glutathione and Gts1p drive beneficial variability in the cadmium resistances of individual yeast cells.
• Hotel room suicide: Las Vegas and Clark County.
• Interferometric determination of the apparent thickness of thin metallic films.
• Loss prevention case of the month--questionable decisions cause deviation.
• Nanoscience and literature: bridging the two cultures.
• Persistent headache: danger!
• Phenotypic heterogeneity can enhance rare-cell survival in 'stress-sensitive' yeast populations.
• Prospective study of the septocutaneous radial free flap and suprafascial donor site.
• Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure.
• Social competence of pre-school, acoustically handicapped children.
• Sudden onset of food poisoning.
• The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs.
• To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation.
• Total synthesis and absolute configuration of laurenditerpenol: a hypoxia inducible factor-1 activation inhibitor.
• Type 2 diabetes and oral antihyperglycemic drugs.
• Who was the doctor of record?
• [METHODS FOR TREATING ASPHYXIA IN NEWBORN INFANTS.]